People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds. Findings of the multi-institutional Phase III trial, which also found that twice-daily radiation treatments offer greater survival benefits than once-daily treatment, were presented. The research comes on the heels of a recent study showing immunotherapy given after radiation and chemotherapy are completed can increase overall survival. Researchers in this new study, the NRG Oncology/Alliance LU005 trial, wanted to test whether there would be a similar benefit when delivering the treatments at the...